Acurx Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

Acurx Pharmaceuticals

14/03/2023 13:57

* Acurx Pharmaceuticals Inc  ACXP.OQ   ACXP.O  is expected
to show
no change in quarterly revenue when it reports  results on March
16. 
    * 
    * ​Refinitiv's mean analyst estimate for Acurx
Pharmaceuticals Inc
is for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acurx
Pharmaceuticals Inc is $14​, above​ its last closing price
of $3.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.27       -0.28      -0.32     Missed  -14.3
  2022                                                  
 Mar. 31 2022              -0.33      -0.26     Beat    21.2​
 Dec. 31 2021  -0.40       -0.40      -0.22     Beat    45
 ​​                                                     
                                                        ​
 This summary was machine generated March 14 at 13:57 GMT.  All
figures in US dollars  unless otherwise stated